These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 35857294)
1. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma. Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168 [TBL] [Abstract][Full Text] [Related]
3. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Barakat O; Wood RP; Ozaki CF; Ankoma-Sey V; Galati J; Skolkin M; Toombs B; Round M; Moore W; Mieles L Liver Transpl; 2010 Mar; 16(3):289-99. PubMed ID: 20209588 [TBL] [Abstract][Full Text] [Related]
4. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698 [TBL] [Abstract][Full Text] [Related]
5. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167 [TBL] [Abstract][Full Text] [Related]
6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436 [TBL] [Abstract][Full Text] [Related]
7. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma. Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388 [TBL] [Abstract][Full Text] [Related]
8. Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria. Murali AR; Romero-Marrero C; Miller C; Aucejo F; Levitin A; Gill A; McLennan G; Karuppasamy K; Zein NN; Lopez R; Menon KV Transplantation; 2016 Nov; 100(11):2391-2397. PubMed ID: 27780187 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479 [TBL] [Abstract][Full Text] [Related]
10. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China. Zhan QF; Ling SB; Deng YN; Shan QN; Ye QW; Xu SJ; Jiang GJ; Lu D; Wei XY; Zhuang L; Zhang W; Shen T; Cen BN; Xie HY; Liu JM; Wu J; Zheng SS; Yang Y; Xu X Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):349-357. PubMed ID: 32622826 [TBL] [Abstract][Full Text] [Related]
11. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741 [TBL] [Abstract][Full Text] [Related]
12. Liver transplantation in hepatocellular carcinoma - should we perform downstaging? Filipec Kanižaj T; Dinjar Kujundžić P; Ostojić A; Mijić M; Sertić Milić H; Mijić A; Mateljak M; Martinčević D; Radetić E; Vidjak V; Kocman B; Mikolašević I Croat Med J; 2022 Aug; 63(4):317-325. PubMed ID: 36046928 [TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453 [TBL] [Abstract][Full Text] [Related]
14. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672 [TBL] [Abstract][Full Text] [Related]
15. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527 [TBL] [Abstract][Full Text] [Related]
16. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. Lei JY; Yan LN; Wang WT World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153 [TBL] [Abstract][Full Text] [Related]
17. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808 [TBL] [Abstract][Full Text] [Related]
18. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545 [TBL] [Abstract][Full Text] [Related]
19. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Sharr WW; Chan SC; Lo CM Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822 [TBL] [Abstract][Full Text] [Related]
20. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. Toso C; Meeberg G; Andres A; Shore C; Saunders C; Bigam DL; Shapiro AMJ; Compagnon P; Berney T; Majno P; Kneteman N Transpl Int; 2019 Feb; 32(2):163-172. PubMed ID: 30152891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]